Elemer Piros, a research analyst at Rodman & Renshaw, is more bullish on Neurochem ( NRMX) and its Alzheimer's drug Alzhemed than I was in my
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.
Independent study monitors concluded that there was "virtually no chance of finding a positive clinical effect."